Patents by Inventor Curt D. Wolfgang

Curt D. Wolfgang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20240016791
    Abstract: R-P88 is used for the treatment of disorders amenable to treatment with an atypical antipsychotic.
    Type: Application
    Filed: September 26, 2023
    Publication date: January 18, 2024
    Inventors: Deepak Phadke, Curt D. Wolfgang, Mihael H. Polymeropoulos, John Joseph Feeney, Gunther Birznieks
  • METHODS FOR TREATING ACUTE MYELOID LEUKEMIA AND RELATED CONDITIONS
    Publication number: 20230414641
    Abstract: Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I) a prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.
    Type: Application
    Filed: June 7, 2023
    Publication date: December 28, 2023
    Applicant: GlycoMimetics, Inc.
    Inventors: Helen M. THACKRAY, Henry H. FLANNER, Curt D. WOLFGANG
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20230330078
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: May 15, 2023
    Publication date: October 19, 2023
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • Methods for treating acute myeloid leukemia and related conditions
    Patent number: 11707474
    Abstract: Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: July 25, 2023
    Assignee: GlycoMimetics, Inc.
    Inventors: Helen M. Thackray, Henry H. Flanner, Curt D. Wolfgang
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20210186948
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: March 3, 2021
    Publication date: June 24, 2021
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • Iloperidone for the treatment of schizophrenia
    Patent number: 10987346
    Abstract: Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof. In one embodiment, the invention provides a method of preventing schizophrenic relapse in an individual diagnosed with schizophrenia, the method comprising: administering to the individual iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof at a daily dose between about 12 mg and about 16 mg following a period in which the individual's schizophrenia was stabilized.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: April 27, 2021
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Curt D. Wolfgang
  • METHODS FOR TREATING ACUTE MYELOID LEUKEMIA AND RELATED CONDITIONS
    Publication number: 20210069220
    Abstract: Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.
    Type: Application
    Filed: March 4, 2019
    Publication date: March 11, 2021
    Inventors: Helen M. THACKRAY, Henry H. FLANNER, Curt D. WOLFGANG
  • ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20210015809
    Abstract: R-P88 is used for the treatment of disorders amenable to treatment with an atypical antipsychotic.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 21, 2021
    Inventors: Deepak Phadke, Curt D. Wolfgang, Mihael H. Polymeropoulos, John Joseph Feeney, Gunther Birznieks
  • Iloperidone metabolite for use in the treatment of psychiatric disorders
    Patent number: 10874659
    Abstract: R-P88 is used for the treatment of disorders amenable to treatment with an atypical antipsychotic.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 29, 2020
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Deepak Phadke, Curt D. Wolfgang, Mihael H. Polymeropoulos, John Joseph Feeney, Gunther Birznieks
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20200206213
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • Method of treatment based on polymorphisms of the KCNQ1 gene
    Patent number: 10563259
    Abstract: The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: February 18, 2020
    Assignee: VANDA PHARMECEUTICALS, INC.
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • ILOPERIDONE FOR THE TREATMENT OF SCHIZOPHRENIA
    Publication number: 20190388412
    Abstract: Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof. In one embodiment, the invention provides a method of preventing schizophrenic relapse in an individual diagnosed with schizophrenia, the method comprising: administering to the individual iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof at a daily dose between about 12 mg and about 16 mg following a period in which the individual's schizophrenia was stabilized.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Inventors: Mihael H. Polymeropoulos, Curt D. Wolfgang
  • Iloperidone for the treatment of schizophrenia
    Patent number: 10441580
    Abstract: Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof. In one embodiment, the invention provides a method of preventing schizophrenic relapse in an individual diagnosed with schizophrenia, the method comprising: administering to the individual iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof at a daily dose between about 12 mg and about 16 mg following a period in which the individual's schizophrenia was stabilized.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: October 15, 2019
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Mihael H. Polymeropoulos, Curt D. Wolfgang
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20190183873
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: February 27, 2019
    Publication date: June 20, 2019
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • Method and composition for treating an alpha adrenoceptor-mediated condition
    Patent number: 10272075
    Abstract: Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: April 30, 2019
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt D. Wolfgang
  • Methods for the administration of iloperidone
    Patent number: 10272076
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: April 30, 2019
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20180110765
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: December 8, 2017
    Publication date: April 26, 2018
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • ILOPERIDONE FOR THE TREATMENT OF SCHIZOPHRENIA
    Publication number: 20180021324
    Abstract: Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof. In one embodiment, the invention provides a method of preventing schizophrenic relapse in an individual diagnosed with schizophrenia, the method comprising: administering to the individual iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof at a daily dose between about 12 mg and about 16 mg following a period in which the individual's schizophrenia was stabilized.
    Type: Application
    Filed: February 17, 2016
    Publication date: January 25, 2018
    Inventors: Mihael H. Polymeropoulos, Curt D. Wolfgang
  • METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE
    Publication number: 20180002756
    Abstract: The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
    Type: Application
    Filed: September 14, 2017
    Publication date: January 4, 2018
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE
    Publication number: 20150368718
    Abstract: The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
    Type: Application
    Filed: September 1, 2015
    Publication date: December 24, 2015
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos